- Home
- GRND vs RCKT Comparison
GRND vs RCKT Comparison
Compare GRND & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRND | RCKT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | 148 | 202 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 534.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRND | RCKT |
|---|---|---|
| Price | $12.37 | $3.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $19.67 | ★ $29.65 |
| AVG Volume (30 Days) | 1.3M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $17.04 | $51.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.79 | $2.19 |
| 52 Week High | $25.13 | $8.26 |
Technical Indicators
Market Signals| Indicator | GRND | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 36.44 |
| Support Level | $11.77 | $3.43 |
| Resistance Level | $14.12 | $3.49 |
| Average True Range (ATR) | 0.48 | 0.39 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 52.21 | 4.83 |
Price Performance
Historical ComparisonAbout GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.